Lipum planerar notering vid Nasdaq First North

Pressmeddelande: Umeå, 28 januari, 2021. Lipum AB med säte i Umeå grundades år 2010. Nu förbereds kapitalanskaffning genom en notering förutsatt godkänd ansökan vid Nasdaq First North Growth Market under våren 2021. Lipum har anlitat G&W Fondkommission att bistå bolaget i processen. Lipum har utvecklat läkemedelskandidaten SOL-116 som har en ny verkningsmekanism med möjlighet att [...]

2021-02-23T11:51:59+00:00

Marina Norberg new CFO at Lipum

Press release: Umeå, January 26, 2020. Lipum AB has appointed Marina Norberg Chief Financial Officer (CFO). Marina Norberg has extensive experience as an approved auditor at PwC and as authorized accounting consultant within Aspia AB, the management team of which she belonged. Marina Norberg will report to CEO Einar Pontén and be part of Lipum's [...]

2021-02-23T11:52:24+00:00

Kallelse till extra bolagsstämma för ändring till publikt aktibolag

Pressmeddelande: Umeå, 15 December 2020. Kallelse till extra bolagsstämma i Lipum AB för ändring till publikt aktiebolag. Aktieägarna i Lipum AB, org.nr 556813-5999, kallas härmed till extra bolagsstämma tisdagen den 29 december 2020. Den extra bolagsstämman hålls för att besluta om styrelsens förslag till fondemission samt ändring av bolagsordningen. Syftet med fondemissionen är att höja [...]

2021-02-23T11:53:35+00:00

KALLELSE TILL EXTRA BOLAGSSTÄMMA

Pressmeddelande: Umeå, 17 August 2020. Kallelse till extra bolagsstämma Aktieägarna i Lipum AB, org. nr. 556813-5999 ("Lipum"), kallas härmed till extra bolagsstämma fredagen den 28 augusti 2020, kl. 12:00 på Tvistevägen 48C i Umeå. Förslag till dagordning och beslut bifogas. Handlingar enligt aktiebolagslagen (2005:551) skickas ut på begäran. Aktieägare som önskar delta i stämman ska [...]

2021-01-04T18:59:42+00:00

Capital raise secures development of Lipum’s novel drug

Press release June 25, 2020 Lipum is supported by Horizon 2020, the EU framework program for research and development, and was granted 23 MSEK for the development of a biological pharmaceutical for treatment of chronic inflammatory diseases. In addition to this grant another 25 MSEK was raised in 2019. Now the capital needed to maintain [...]

2020-06-26T11:07:30+00:00

Dr Kristian Sandberg suggested as new board member

Press release Februari 18, 2020 The board of directors of Lipum AB has suggested Dr Kristian Sandberg to be elected as new member of the board at an extraordinary general meeting held in Umeå on March 3, 2020. Lipum has identified bile salt-stimulated lipase (BSSL) as a novel target for treatment of chronic inflammatory diseases. [...]

2020-02-18T08:00:03+00:00

Professor Anders Fasth joins the scientific advisory board

Press release November 29, 2019 Lipum has developed a biological drug candidate for treatment of chronic inflammatory diseases and aim for a better treatment of juvenile idiopathic arthritis (JIA), that affects children. Therefore, the scientific advisory board of the company is now strengthened with Anders Fasth, senior professor of pediatric immunology at the University of [...]

2020-06-26T11:16:43+00:00
Go to Top